Ειδήσεις: IONIS PHARMACEUTICALS | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

26/03 11:57 defenseworld.net

DAVENPORT & Co LLC Purchases 155,334 Shares of Ionis Pharmaceuticals, Inc. $IONS

Davenport & Co Ionis Pharmaceuticals 13F filing Q4 investment share purchase biopharma

26/03 11:15 defenseworld.net

Ionis Pharmaceuticals (NASDAQ:IONS) Given New $105.00 Price Target at Needham & Company LLC

Ionis Pharmaceuticals IONS price target Needham & Company buy rating stock

26/03 10:39 defenseworld.net

HC Wainwright Issues Positive Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price

Ionis Pharmaceuticals HC Wainwright price target buy rating biotech Leerink Partners

18/03 16:13 yahoo.com

Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pipeline Supported Leerink’s Higher Target

Ionis Pharmaceuticals Catalyst pipeline Leerink 2026 outlook RNA therapeutics revenue growth

18/03 16:13 yahoo.com

Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pipeline Supported Leerink’s Higher Target

Ionis Pharmaceuticals Catalyst pipeline Leerink 2026 outlook RNA therapeutics revenue growth

Loading...